Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blue Mesa Health

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

Lucid Group brings creative and digital magic to the mix with the acquisition of Bluedog

Lucid Group is delighted to announce its first acquisition, welcoming colleagues from creative and digital consultancy Bluedog into its magic kingdom.Over the last twelve years, Lucid Group has become well...

Lucid Group Communications Limited

- PMLiVE

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

Partners to co-develop novel bifunctional fusion protein

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

- PMLiVE

Novo Nordisk preps for speedy oral GLP-1 drug filing

Needs to compete with rival's fast-growing Trulicity

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

Live Webinar: Poker face revealed: Using facial analysis to reveal deeper emotional insights

Thursday 28th February 2019, 10:00 EST / 15:00 GMT / 16:00 CET

Research Partnership

Sanofi reception

FDA adcomm split on Sanofi’s type 1 diabetes drug

Concerns rose after Zynquista-treated patients showed an eight-fold increase in DKA

- PMLiVE

NHS tech leader departs for digital GP service

Hands baton over to Health Innovation Network chief

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Zafgen shares tumble after FDA places hold on diabetes trial

Regulator concerns based on deaths with previous drug

- PMLiVE

Abbott’s wearable glucose monitor to be available across England

FreeStyle Libre will be prescribed to those with T1 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links